PLATINUM-RESISTANT OVARIAN CANCER
Clinical trials for PLATINUM-RESISTANT OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-RESISTANT OVARIAN CANCER trials appear
Sign up with your email to follow new studies for PLATINUM-RESISTANT OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for tough ovarian cancer: Rina-S faces off against standard chemo in major trial
Disease control OngoingThis study tests a new drug called Rina-S against standard chemotherapy for people with ovarian cancer that no longer responds to platinum-based treatments. About 530 participants will be randomly assigned to receive either Rina-S or one of four approved chemo drugs. The goal is …
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated May 26, 2026 03:16 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called TransCon IL-2 β/γ, given alone or with other cancer treatments, for adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find safe doses and check for side effects. About 320 partici…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: Ascendis Pharma Oncology Division A/S • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New hope for hard-to-treat ovarian cancer: experimental combo shows promise
Disease control OngoingThis study tests whether adding the experimental drug NP-G2-044 (Prilukae) to standard chemotherapy (PLD) can help people with platinum-resistant ovarian cancer, a type that has stopped responding to initial treatments. About 380 participants will receive either the combination o…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE2, PHASE3 • Sponsor: Novita Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 18, 2026 12:00 UTC
-
Virus plus immunotherapy shows promise against resistant ovarian cancer
Disease control OngoingThis early-stage trial tests a specially designed virus (TILT-123) that targets and kills cancer cells while also boosting the immune system. It is given together with the immunotherapy drug pembrolizumab (Keytruda) and sometimes chemotherapy, to women with ovarian cancer that no…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: TILT Biotherapeutics Ltd. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC